Clik here to view.
New Drug Monograph for Nexafed
A new formulation of the decongestant pseudoephedrine will be available to consumers that impedes the extraction and conversion of pseudoephedrine to methamphetamine. Learn more at www.epocrates.com
View ArticleClik here to view.
MedWatch Safety Alert for Incivek
The FDA recently added a boxed warning to the prescribing information for the hepatitis C protease inhibitor, Incivek (telaprevir). The FDA received reports of serious skin reactions, including some...
View ArticleClik here to view.
MedWatch Safety Alert for Zolpidem
The FDA recently recommended a lower bedtime dose of zolpidem products (including generic formulations, Ambien, Ambien CR, Edluar, and Zolpimist) due to the risk for next-morning impairment. Blood...
View ArticleClik here to view.
New Drug Monograph for Cometriq
The FDA recently approved the tyrosine kinase inhibitor, Cometriq (cabozantinib), to treat progressive, metastatic medullary thyroid cancer. Learn more at www.epocrates.com
View ArticleClik here to view.
MedWatch Safety Alert for Samsca
The FDA recently notified healthcare professionals about the risk of liver toxicity associated with Samsca (tolvaptan). Although the data came from a trial using higher doses for an off-label...
View ArticleClik here to view.
New Drug Monograph for Eliquis
The FDA recently approved the oral factor Xa inhibitor, Eliquis (apixaban), to prevent thromboembolism and stroke in adult patients with nonvalvular atrial fibrillation. Learn more at www.epocrates.com
View ArticleClik here to view.
New Drug Monograph for Flublok
The FDA recently approved Flublok, a seasonal influenza vaccine made using an insect virus expression system and recombinant DNA technology, rather than influenza virus or eggs in its production....
View ArticleClik here to view.
MedWatch Safety Alert for Omontys
The FDA recently notified healthcare professionals about post-marketing reports of serious hypersensitivity reactions, including life-threatening and fatal anaphylaxis, associated with Omontys...
View ArticleClik here to view.
New Drug Monograph for Kynamro
The FDA recently approved Kynamro (mipomersen), a once-weekly subcutaneous therapy that inhibits the translation of apo B-100 mRNA, thereby preventing the formation of LDL and VLDL. Kynamro is...
View ArticleClik here to view.
MedWatch Safety Alert for Azithromycin
The FDA recently notified the public about the risk of QT prolongation and potentially fatal arrhythmias associated with azithromycin (Zithromax, Zmax). Healthcare professionals should weigh the risk...
View ArticleClik here to view.
New Drug Monograph for Signifor
The FDA recently approved the injectable somatostatin analog, Signifor (pasireotide), to treat Cushing disease in adult patients either refractory to, or not candidates for, pituitary surgery. The drug...
View ArticleClik here to view.
New Drug Monograph for Abilify Maintena
The FDA recently approved the once-monthly intramuscular injection of the atypical antipsychotic drug, aripiprazole (Abilify Maintena), to treat schizophrenia in adult patients. Learn more at...
View ArticleClik here to view.
New Drug Monograph for Tecfidera
The FDA recently approved the oral drug, Tecfidera (dimethyl fumarate), to treat relapsing forms of multiple sclerosis in adult patients. Learn more at www.epocrates.com
View ArticleClik here to view.
New Drug Monograph for Invokana
The FDA recently approved the oral drug, Invokana (canagliflozin), to treat type 2 diabetes mellitus in adult patients. Canaglifozin is the first in a new class of sodium-glucose cotransporter 2...
View ArticleClik here to view.
MedWatch Safety Alert for Potiga
The FDA recently warned about the anticonvulsant, Potiga (ezogabine), relating to reports of blue skin discoloration and pigment changes in the retina. All patients starting or taking Potiga should...
View ArticleClik here to view.
MedWatch Safety Alert for Valproate Products
The FDA recently advised against the use of valproate products (valproate sodium, valproic acid, divalproex sodium; brands include Depacon, Depakene, Stavzor, Depakote) in pregnant women to prevent...
View ArticleClik here to view.
Boxed Warning Added to Pradaxa
A boxed warning was recently added to the prescribing information for the oral anticoagulant, Pradaxa (dabigatran etexilate). Discontinuing treatment may increase the risk of thrombotic events,...
View ArticleClik here to view.
MedWatch Safety Alert for Zolpidem
The FDA recently updated the safety alert for zolpidem (Ambien, Ambien CR, Edluar, Intermezzo, Zolpimist, and generics). Based on the risk for next-morning impairment associated with this insomnia...
View ArticleClik here to view.
Expanded Pediatric Dosing for Sustiva
The FDA recently approved the once daily non-nucleoside reverse transcriptase inhibitor, Sustiva (efavirenz), as part of a regimen to treat HIV-1 infection in children who are at least 3 months old and...
View ArticleClik here to view.
MedWatch Safety Alert for Magnesium Sulfate
The FDA recently cautioned against the off-label tocolytic use of magnesium sulfate for more than 5-7 days. Continuous administration to pregnant women for pre-term labor may lead to hypocalcemia,...
View Article
